239000000969 carrier Substances 0.000 claims description 8.
Assignors: WILLIAMS, PHILIP DAVID Application granted granted Critical Publication of US5896390A publication Critical patent/US5896390A/en Anticipated expiration legal-status Critical Status Expired - Lifetime legal-status Critical Current Links ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Application filed by Adtran Inc filed Critical Adtran Inc Priority to US08/803,986 priority Critical patent/US5896390A/en Assigned to ADTRAN, INC. Original Assignee Adtran Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Lifetime Application number US08/803,986 Inventor Philip David Williams Current Assignee (The listed assignees may be inaccurate.
ISDN SUB LINGUAN UNTUK PDF
Google Patents Two wire, sub-rate 2B1Q ISDN architectureĭownload PDF Info Publication number US5896390A US5896390A US08/803,986 US80398697A US5896390A US 5896390 A US5896390 A US 5896390A US 80398697 A US80398697 A US 80398697A US 5896390 A US5896390 A US 5896390A Authority US United States Prior art keywords dds wire rate isdn site Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US5896390A - Two wire, sub-rate 2B1Q ISDN architecture Thus, severe tolerance to ISDN abolishes the anti-ischaemic effects of NTG, and appropriate regimens of ISDN have considerable anti-anginal effects during chronic administration.US5896390A - Two wire, sub-rate 2B1Q ISDN architecture Following once-daily therapy ISDN prolonged WTI ( p < 0.0001) by 27.2% after an 80 mg dose and by 36.2% after a dose of 120 mg. Six hours after the first 80 mg ISDN ingestion WTI improved ( p < 0.0001) by 66.0%, and after 120 mg by 58.4%. However, NTG did not improve WTI in q.i.d. After long-term OP therapy NTG prolonged WTI ( p < 0.01) by 15.6%, during once-daily ISDN treatment, an 80 mg dose prolonged WTI by 22.8% and a dose of 120 mg by 36.5%. In the first ingestion NTG significantly improved WTI ( p < 0.0001) by 42.7% after OP, by 46.5% after 80 mg ISDN and by 52.1% after 120 mg. The efficacy of NTG was evaluated by analyzing walking time to ischaemia (WTI) during exercise tests performed 5 minutes after NTG or SLP administration, and the efficacy of ISDN 2 h and 6 h after oral ingestion. The same pattern was used in the first ingestion and in long-term OP or ISDN therapy for 7 days (OP and ISDN every 6 h, and ISDN once daily). All patients received either NTG 0.5 mg or sublingual placebo (SLP) 2.5 h after OP ingestion, but only NTG 2.5 h after ISDN. In a double-blind crossover design study 38 men with stable angina initially received either an oral placebo (OP) or ISDN. The purpose of this study was to evaluate the efficacy of sublingual nitroglycerin (NTG) during treatment with oral sustained-release isosorbide dinitrate (ISDN) in two doses: 80 mg and 120 mg.
0 kommentar(er)
